Tumor neoantigens (derived from tumor somatic mutations or aberrant mRNA processing) are peptides that are absent from normal human tissues and potentially recognized by TCRs if presented by MHC molecules [24–27]. The gene discussed is HLA-C; the disease is neoplasm.